Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends a Variation to the Terms of Marketing Authorisation for Regorafenib

New indication concerns treatment of patients with unresectable or metastatic GIST who progressed on or are intolerant to imatinib and sunitinib
30 Jun 2014
Sarcomas;  Anticancer agents & Biologic therapy

On 26 June 2014, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product regorafenib (Stivarga). The marketing authorisation holder for this medicinal product is Bayer Pharma AG. They may request a re-examination of the CHMP opinion, provided that they notify the EMA in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted a new indication as follows:

Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.

Detailed conditions for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised European public assessment report, and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full indications for regorafenib will be as follows:

Stivarga is indicated for the treatment of adult patients with:

  • metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine based chemotherapy, an anti VEGF therapy and an anti EGFR therapy.
  • unresectable or metastatic GISTs who progressed on or are intolerant to prior treatment with imatinib and sunitinib.
Last update: 30 Jun 2014

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.